TABLE OF CONTENTS Executive Summary ............................................................................................................................. 3 Section 1: Population for Antibody Treatment and Regulatory Notices ............................................. 4 Mandatory Requirements for Bamlanivimab Administration Under Emergency Use Authorization .............................................7 Important Safety Information ......................................................................................................................................................... 9 Section 2: Supply and Scale of Effort ................................................................................................. 10 Product Allocation and Supply ...................................................................................................................................................... 11 Scaling Operations ........................................................................................................................................................................ 11 Section 3: Allocation and Ordering ..................................................................................................... 12 Flow of Allocated Product ............................................................................................................................................................. 14 Section 4: Infusion Site of Care Requirements .................................................................................. 15 Preparation, Storage and Handling .............................................................................................................................................. 16 Compatible Materials ................................................................................................................................................................... 17 Preparation and Administration ................................................................................................................................................... 17 Preparation Summary Table for 700mg Dose of Bamlanivimab Solution for Intravenous Infusion ........................................... 19 Section 5: Recommended Infusion Site of Care Resources and Equipment Considerations .......... 20 Staffing Recommendations .......................................................................................................................................................... 21 Infusion Site of Care Materials ..................................................................................................................................................... 22 Section 6: Education and Awareness ................................................................................................. 23 Appendix A: Lilly Monoclonal Antibody Clinical Trial Modeling Information .................................. 27 Appendix B: Basic Equipment Recommendations ............................................................................. 29 Lilly Bamlanivimab Antibody Playbook | 2 PP-BM-US-0024